Neutralizing Activity of Broadly Neutralizing anti-HIV-1 Antibodies against Primary African Isolates.


Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
01 03 2021
Historique:
entrez: 10 12 2020
pubmed: 11 12 2020
medline: 11 12 2020
Statut: ppublish

Résumé

Novel therapeutic and preventive strategies are needed to contain the HIV-1 epidemic. Broadly neutralizing human antibodies (bNAbs) with exceptional activity against HIV-1 are currently being tested in HIV-1 prevention trials. The selection of anti-HIV-1 bNAbs for clinical development was primarily guided by their

Identifiants

pubmed: 33298542
pii: JVI.01909-20
doi: 10.1128/JVI.01909-20
pmc: PMC8092834
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : UM1 AI100663
Pays : United States

Informations de copyright

Copyright © 2020 Lorenzi et al.

Références

Cell. 2020 Feb 6;180(3):471-489.e22
pubmed: 32004464
Sci Transl Med. 2017 Jan 18;9(373):
pubmed: 28100831
Proc Natl Acad Sci U S A. 2016 Dec 6;113(49):E7908-E7916
pubmed: 27872306
J Virol. 2014 Nov;88(21):12669-82
pubmed: 25142607
J Virol. 2015 Oct 14;90(1):76-91
pubmed: 26468542
PLoS One. 2019 Aug 8;14(8):e0219142
pubmed: 31393868
Sci Transl Med. 2015 Dec 23;7(319):319ra206
pubmed: 26702094
Lancet HIV. 2019 May;6(5):e297-e306
pubmed: 31000477
J Virol. 2005 Aug;79(16):10108-25
pubmed: 16051804
J Virol. 2010 Oct;84(20):10510-21
pubmed: 20686044
Curr Opin HIV AIDS. 2019 May;14(3):153-160
pubmed: 30882484
Virology. 2005 Sep 1;339(2):226-38
pubmed: 16005039
J Exp Med. 2018 Sep 3;215(9):2311-2324
pubmed: 30072495
J Virol. 2014 Dec;88(23):13910-7
pubmed: 25231299
AIDS. 2009 Aug 24;23(13):1659-67
pubmed: 19581791
J Virol. 2015 Mar;89(5):2659-71
pubmed: 25520506
Nucleic Acids Res. 2015 Jul 1;43(W1):W213-9
pubmed: 26044712
Nature. 2015 Jun 25;522(7557):487-91
pubmed: 25855300
Nature. 2016 Jul 28;535(7613):556-60
pubmed: 27338952
J Virol. 2019 Mar 5;93(6):
pubmed: 30567994
J Virol. 2018 Feb 12;92(5):
pubmed: 29237833
Science. 2009 Oct 9;326(5950):285-9
pubmed: 19729618
J Virol. 2008 Jun;82(12):5807-14
pubmed: 18385254
Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17624-9
pubmed: 25422458
Immunity. 2018 May 15;48(5):872-895
pubmed: 29768175
J Virol Methods. 2007 Jul;143(1):104-11
pubmed: 17416428
N Engl J Med. 2016 Nov 24;375(21):2037-2050
pubmed: 27959728
Science. 2011 Sep 16;333(6049):1633-7
pubmed: 21764753
PLoS One. 2011;6(12):e28632
pubmed: 22174851
PLoS Med. 2017 Nov 14;14(11):e1002435
pubmed: 29136037
Virology. 2012 May 25;427(1):25-33
pubmed: 22369748
PLoS Comput Biol. 2017 Oct 24;13(10):e1005789
pubmed: 29065122
Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):E3268-77
pubmed: 23115339
Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):10598-603
pubmed: 23754383
N Engl J Med. 2010 Feb 4;362(5):427-39
pubmed: 20089951
N Engl J Med. 2012 Aug 2;367(5):399-410
pubmed: 22784037
Nature. 2018 Sep;561(7724):479-484
pubmed: 30258136
Nat Med. 2018 Nov;24(11):1701-1707
pubmed: 30258217
J Virol. 2017 Sep 12;91(19):
pubmed: 28747500
J Virol Methods. 2015 Mar;214:46-53
pubmed: 25681527
PLoS Pathog. 2013;9(7):e1003477
pubmed: 23853594
J Virol. 2010 May;84(9):4311-20
pubmed: 20164234
Nat Med. 2017 Feb;23(2):185-191
pubmed: 28092665
Syst Biol. 2010 May;59(3):307-21
pubmed: 20525638
Science. 2010 Aug 13;329(5993):856-61
pubmed: 20616233
Bioinformatics. 2010 Aug 1;26(15):1899-900
pubmed: 20427515
PLoS Pathog. 2018 Mar 5;14(3):e1006860
pubmed: 29505593
Curr Protoc Immunol. 2005 Jan;Chapter 12:Unit 12.11
pubmed: 18432938

Auteurs

Julio C C Lorenzi (JCC)

Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA.

Pilar Mendoza (P)

Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA.

Yehuda Z Cohen (YZ)

Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA.

Lilian Nogueira (L)

Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA.

Christy Lavine (C)

Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.

Joseph Sapiente (J)

Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.

Marie Wiatr (M)

Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA.

Nelly R Mugo (NR)

Kenya Medical Research Institute (KEMRI), Nairobi, Kenya.
Department of Global Health, University of Washington, Seattle, Washington, USA.

Andrew Mujugira (A)

Infectious Diseases Institute, Makerere University, Kampala, Uganda.

Sinead Delany (S)

University of the Witswatersrand, South Africa.

Jairam Lingappa (J)

Department of Global Health, University of Washington, Seattle, Washington, USA.
Department of Medicine, University of Washington, Seattle, Washington, USA.
Department of Pediatrics, University of Washington, Seattle, Washington, USA.

Connie Celum (C)

Department of Global Health, University of Washington, Seattle, Washington, USA.
Department of Medicine, University of Washington, Seattle, Washington, USA.
Department of Epidemiology, University of Washington, Seattle, Washington, USA.

Michael S Seaman (MS)

Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.

Marina Caskey (M)

Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA.

Michel C Nussenzweig (MC)

Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA nussen@rockefeller.edu.
Howard Hughes Medical Institute.

Classifications MeSH